Core Viewpoint - The FDA has approved Zepbound (tirzepatide) as the first drug for treating obstructive sleep apnea in patients with obesity, expanding treatment options beyond traditional methods like CPAP machines [3][4]. Group 1: Drug Approval and Indications - Zepbound is officially indicated for moderate-to-severe obstructive sleep apnea in adults with obesity [4]. - The approval follows a significant study published in the New England Journal of Medicine, demonstrating improvements in both sleep apnea and obesity among patients [4][5]. Group 2: Implications for Patients and Healthcare - The introduction of Zepbound provides new treatment avenues for sleep apnea patients who previously had limited options due to co-morbidities [5]. - There is potential for the FDA to approve additional weight loss drugs for treating sleep apnea in the future, as indicated by medical professionals [4].

Company Overview - Eli Lilly and Company (LLY) received FDA approval for its drug Omvoh (mirikizumab) for treating Crohn's disease (CD), marking its second inflammatory bowel disease (IBD) indication after ulcerative colitis (UC) [1][2] - Omvoh is currently approved for UC in 44 countries and has shown significant clinical results in studies [1][2] Clinical Data - The approval for CD was based on the VIVID 1 study, which met its co-primary endpoints, demonstrating significant improvement in clinical remission and endoscopic response at one year [2] - In the VIVID-2 open-label extension study, nearly 90% of patients who achieved clinical remission at one year maintained it with two years of continuous treatment [3] Market Expansion - Lilly is seeking approval for Omvoh for CD in several countries, including the EU and Japan, with a positive opinion from the EMA's CHMP for the EU approval expected soon [4] - The IBD market is experiencing increased demand due to rising prevalence rates and favorable reimbursement policies in developed countries [5][6] Competitive Landscape - Major pharmaceutical companies are actively developing new treatments for IBD, with Lilly acquiring Morphic Therapeutics to enhance its pipeline [7] - AbbVie has been acquiring smaller biotechs and expanding its IBD portfolio, while Merck and Sanofi are also making strategic acquisitions and partnerships to strengthen their positions in the IBD market [9][10][11] Stock Performance - Lilly's stock has increased by 18.7% over the past year, contrasting with a 3.9% decline in the industry [3]

该药此前已于2023年10月获准用于治疗成人溃疡性结肠炎。 校对：刘榕枝 克罗恩病是一种炎症性肠病，可导致慢性腹痛。 证券时报网讯，礼来表示，该公司治疗中度至重度活动性克罗恩病的药物已获得美国食品药品管理局 (FDA)的批准。 ...

Core Insights - Eli Lilly and Company announced the FDA approval of Omvoh® (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease in adults, following its earlier approval for ulcerative colitis in October 2023 [1][5][10] - Omvoh targets interleukin-23p19 (IL-23p19) to reduce gastrointestinal inflammation and is the first biologic treatment in over 15 years to present two-year Phase 3 efficacy data for Crohn's disease at the time of approval [1][10] Group 1: Clinical Trial Results - In the Phase 3 VIVID-1 trial, 53% of patients treated with Omvoh achieved clinical remission at one year compared to 36% on placebo (p<0.001) [4] - 46% of Omvoh patients had visible healing of the intestinal lining at one year versus 23% on placebo (p<0.001) [4] - Among patients who achieved clinical remission and endoscopic response at one year, nearly 90% maintained clinical remission with two years of continuous Omvoh treatment [1][3] Group 2: Ongoing Studies and Safety Profile - Omvoh is being evaluated in the ongoing VIVID-2 study, which assesses its efficacy and safety for up to three years in adults with Crohn's disease [3] - The overall safety profile of Omvoh in Crohn's disease patients is consistent with its profile in ulcerative colitis patients, with common adverse reactions including upper respiratory tract infections and injection site reactions [3][6] Group 3: Market and Accessibility - Lilly has submitted marketing applications for Omvoh in Crohn's disease globally, including in the European Union and Japan, and it is currently approved in 44 countries for ulcerative colitis [5][6] - As of January 1, Omvoh has gained first-line biologic coverage from two of the three largest pharmacy benefit managers, enhancing patient access [6][7]

If you'd like to learn more about how to best position yourself in under valued stocks mispriced by the market to start 2025, consider joining Out Fox The Street .Mark leads the investing group Out Fox The Street where he shares stock picks and deep research to help readers uncover potential multibaggers while managing portfolio risk via diversification. Features include various model portfolios, stock picks with identifiable catalysts, daily updates, real-time alerts, and access to community chat and direc ...

Eli Lilly and Company (LLY) dropped 6.6% in the Jan. 14 trading session after slashing its revenue guidance for the fourth quarter and fiscal 2024, citing lower-than-expected sales for its weight-loss medicine Zepbound and diabetes treatment Mounjaro. However, the drugmaker offered solid guidance for 2025, underscoring the strong growth prospects.Investors seeking to buy the dip could bet on ETFs having the largest exposure to the drugmaker. These include iShares U.S. Pharmaceuticals ETF (IHE) , Roundhill G ...

Eli Lilly and Company’s (LLY) shares declined 6.6% on Tuesday after the company lowered its sales guidance for full-year 2024 and announced disappointing preliminary fourth-quarter sales numbers. The company also issued its total revenue guidance for 2025 at the JP Morgan Healthcare Conference.Lilly’s total revenues for the fourth quarter fell short of expectations due to lower-than-expected sales of its popular GLP-1 drugs, Mounjaro for type II diabetes and Zepbound for obesity. In addition, lower-than-exp ...

Company Overview - Eli Lilly's stock (NYSE: LLY) experienced a decline of over 6% on January 14 due to slower than expected growth in obesity drug sales, leading to a downward adjustment of Q4 revenue forecast by 5% to $13.5 billion, which is $500 million below analysts' consensus estimate of $14 billion [1] - For the full year 2024, Eli Lilly projects revenues of $45 billion, indicating a 32% growth over 2023, but still falling short of the $45.4 billion consensus estimate [1] Future Outlook - Despite the recent stock decline, the company's outlook for 2025 is strong, with projected revenues between $58 billion and $61 billion, reflecting a 32% growth at the midpoint compared to the expected 2024 revenue [3] - Eli Lilly has a robust pipeline with drugs in clinical trials across various therapeutic areas, including a potential regulatory approval for a new weight-loss drug, orforglipron, expected next year [4] Market Performance - Eli Lilly has consistently outperformed the broader market over the past four years, with its stock generating better returns than the S&P 500 [5] - The current dip in LLY stock is viewed as an opportunity for long-term investors, with analysts estimating an average price target of $985, indicating over 30% upside from current levels [6]

Eli Lilly (LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 billion. For a while, it looked like it might be on track to be the first healthcare company to top a $1 trillion valuation, perhaps as early as this year.But over the past three months, the stock has fallen by 14% as the recent election results don't appear to be inspiring much enthusiasm around the business. Fears of heightened oversight in the industry could weigh on not just Eli Lilly, ...

Eli Lilly (NYSE: LLY) saw its stock decline sharply by 6.5% on January 14, following the release of its fourth-quarter 2024 revenue guidance, which fell short of Wall Street expectations.The pharmaceutical giant now projects $13.5 billion in revenue for the quarter, sparking concerns over the performance of its blockbuster weight-loss and diabetes drugs, Mounjaro and Zepbound.As of the market close on January 14, Eli Lilly’s stock was trading at $744.91, reflecting a one-day loss of over 6.5%. On the five-d ...